24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2010-06, Vol.33 (6), p.1176-1178 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1178 |
|---|---|
| container_issue | 6 |
| container_start_page | 1176 |
| container_title | Diabetes care |
| container_volume | 33 |
| creator | Swinnen, Sanne G Dain, Marie-Paule Aronson, Ronnie Davies, Melanie Gerstein, Hertzel C Pfeiffer, Andreas F Snoek, Frank J DeVries, J. Hans Hoekstra, Joost B Holleman, Frits |
| description | OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C |
| doi_str_mv | 10.2337/dc09-2294 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2875419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A228905609</galeid><sourcerecordid>A228905609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-f15698e0c2c50295430020585a74250ea0cdde335fcdb40a94e1e389095457473</originalsourceid><addsrcrecordid>eNpt0lFv0zAQAOAIgdgoPPAHIBpCCGkZjmM38QvS1EKZVKkIOu3Rcp1L5pHYnZ0wlT_K3-FCS2GoykNk-_P5fL4oep6SM5pl-btSE5FQKtiD6DgVGU84Z8XD6JikTCRcCHoUPQnhhhDCWFE8jo4ooYRkJD2OflKWXAF8O42_KFu61vyA8jReelBd0rlkqXwNHY6NauKJa9fKG1vHF9Z0RnXG2dhVOAp9Y2w8a1AbC_HCakimyjSb-Mp013swhQ5a4-PlndkDnP6MkcB2YYuXmzXENJ4atUIecLMq4bZXHaCeONt51zRQxnj2wmNWs6bXLkAyd3fwO7mp7-vwNHpUqSbAs91_FF1-_LCcfErmi9nF5HyeaD4mXVKlfCwKIJpqTqjgLCNYGl5wlTPKCSiiyxKyjFe6XDGiBIMUskIQpDxneTaK3m_jrvtVC6XGe2BScu1Nq_xGOmXk_RVrrmXtvkta5JzhY42iN7sA3t32EDrZmqChaZQF1weZZ1lKxuMiRXnyn7xxvbd4OzlGgZ1AhnCvtqhWDUhjK4en6iGkPKcUE8drDyo5oGqwgCk6C5XB6Xv-7IDHr8T31Ac3vN1u0N6F4KHaVyQlcuhZOfSsHHoW7Yt_S7iXf5oUwesdUEGrpvLKahP-OixlIThH93LrKuWkqj2ay68UA5C0YLnAYv8C2Bn8vA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>606623309</pqid></control><display><type>article</type><title>24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Swinnen, Sanne G ; Dain, Marie-Paule ; Aronson, Ronnie ; Davies, Melanie ; Gerstein, Hertzel C ; Pfeiffer, Andreas F ; Snoek, Frank J ; DeVries, J. Hans ; Hoekstra, Joost B ; Holleman, Frits</creator><creatorcontrib>Swinnen, Sanne G ; Dain, Marie-Paule ; Aronson, Ronnie ; Davies, Melanie ; Gerstein, Hertzel C ; Pfeiffer, Andreas F ; Snoek, Frank J ; DeVries, J. Hans ; Hoekstra, Joost B ; Holleman, Frits</creatorcontrib><description>OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C <7% without symptomatic hypoglycemia [less-than or equal to]3.1 mmol/l. RESEARCH DESIGN AND METHODS: In this 24-week trial, 973 insulin-naive type 2 diabetic patients on stable oral glucose-lowering drugs with A1C 7.0-10.5% were randomized to glargine once daily or detemir twice daily. Insulin doses were systematically titrated. RESULTS: 27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were -1.46 ± 1.09% for glargine and -1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017). Hypoglycemia risk was similar. Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001). Glargine doses were lower than detemir doses: 43.5 ± 29.0 vs. 76.5 ± 50.5 units/day (P < 0.001). CONCLUSIONS: In insulin-naive type 2 diabetic patients, glargine reached similar control as detemir, with more weight gain, but required significantly lower doses.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc09-2294</identifier><identifier>PMID: 20200301</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Administration, Oral ; Biological and medical sciences ; Clinical trials ; Comparative analysis ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes. Impaired glucose tolerance ; Dosage and administration ; Drug Administration Schedule ; Drug therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Glycated Hemoglobin A - metabolism ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacology ; Insulin - administration & dosage ; Insulin - analogs & derivatives ; Insulin - pharmacology ; Insulin - therapeutic use ; Insulin Detemir ; Insulin Glargine ; Insulin, Long-Acting ; Medical sciences ; Metabolic diseases ; Miscellaneous ; Original Research ; Patient outcomes ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Quality of life ; Studies ; Treatment Outcome ; Type 2 diabetes ; Weight Gain - drug effects</subject><ispartof>Diabetes care, 2010-06, Vol.33 (6), p.1176-1178</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 American Diabetes Association</rights><rights>Copyright American Diabetes Association Jun 2010</rights><rights>2010 by the American Diabetes Association. 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-f15698e0c2c50295430020585a74250ea0cdde335fcdb40a94e1e389095457473</citedby><cites>FETCH-LOGICAL-c560t-f15698e0c2c50295430020585a74250ea0cdde335fcdb40a94e1e389095457473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22878955$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20200301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Swinnen, Sanne G</creatorcontrib><creatorcontrib>Dain, Marie-Paule</creatorcontrib><creatorcontrib>Aronson, Ronnie</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><creatorcontrib>Gerstein, Hertzel C</creatorcontrib><creatorcontrib>Pfeiffer, Andreas F</creatorcontrib><creatorcontrib>Snoek, Frank J</creatorcontrib><creatorcontrib>DeVries, J. Hans</creatorcontrib><creatorcontrib>Hoekstra, Joost B</creatorcontrib><creatorcontrib>Holleman, Frits</creatorcontrib><title>24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C <7% without symptomatic hypoglycemia [less-than or equal to]3.1 mmol/l. RESEARCH DESIGN AND METHODS: In this 24-week trial, 973 insulin-naive type 2 diabetic patients on stable oral glucose-lowering drugs with A1C 7.0-10.5% were randomized to glargine once daily or detemir twice daily. Insulin doses were systematically titrated. RESULTS: 27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were -1.46 ± 1.09% for glargine and -1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017). Hypoglycemia risk was similar. Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001). Glargine doses were lower than detemir doses: 43.5 ± 29.0 vs. 76.5 ± 50.5 units/day (P < 0.001). CONCLUSIONS: In insulin-naive type 2 diabetic patients, glargine reached similar control as detemir, with more weight gain, but required significantly lower doses.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Dosage and administration</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - analogs & derivatives</subject><subject>Insulin - pharmacology</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Detemir</subject><subject>Insulin Glargine</subject><subject>Insulin, Long-Acting</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Quality of life</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes</subject><subject>Weight Gain - drug effects</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0lFv0zAQAOAIgdgoPPAHIBpCCGkZjmM38QvS1EKZVKkIOu3Rcp1L5pHYnZ0wlT_K3-FCS2GoykNk-_P5fL4oep6SM5pl-btSE5FQKtiD6DgVGU84Z8XD6JikTCRcCHoUPQnhhhDCWFE8jo4ooYRkJD2OflKWXAF8O42_KFu61vyA8jReelBd0rlkqXwNHY6NauKJa9fKG1vHF9Z0RnXG2dhVOAp9Y2w8a1AbC_HCakimyjSb-Mp013swhQ5a4-PlndkDnP6MkcB2YYuXmzXENJ4atUIecLMq4bZXHaCeONt51zRQxnj2wmNWs6bXLkAyd3fwO7mp7-vwNHpUqSbAs91_FF1-_LCcfErmi9nF5HyeaD4mXVKlfCwKIJpqTqjgLCNYGl5wlTPKCSiiyxKyjFe6XDGiBIMUskIQpDxneTaK3m_jrvtVC6XGe2BScu1Nq_xGOmXk_RVrrmXtvkta5JzhY42iN7sA3t32EDrZmqChaZQF1weZZ1lKxuMiRXnyn7xxvbd4OzlGgZ1AhnCvtqhWDUhjK4en6iGkPKcUE8drDyo5oGqwgCk6C5XB6Xv-7IDHr8T31Ac3vN1u0N6F4KHaVyQlcuhZOfSsHHoW7Yt_S7iXf5oUwesdUEGrpvLKahP-OixlIThH93LrKuWkqj2ay68UA5C0YLnAYv8C2Bn8vA</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Swinnen, Sanne G</creator><creator>Dain, Marie-Paule</creator><creator>Aronson, Ronnie</creator><creator>Davies, Melanie</creator><creator>Gerstein, Hertzel C</creator><creator>Pfeiffer, Andreas F</creator><creator>Snoek, Frank J</creator><creator>DeVries, J. Hans</creator><creator>Hoekstra, Joost B</creator><creator>Holleman, Frits</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100601</creationdate><title>24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs</title><author>Swinnen, Sanne G ; Dain, Marie-Paule ; Aronson, Ronnie ; Davies, Melanie ; Gerstein, Hertzel C ; Pfeiffer, Andreas F ; Snoek, Frank J ; DeVries, J. Hans ; Hoekstra, Joost B ; Holleman, Frits</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-f15698e0c2c50295430020585a74250ea0cdde335fcdb40a94e1e389095457473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Dosage and administration</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - analogs & derivatives</topic><topic>Insulin - pharmacology</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Detemir</topic><topic>Insulin Glargine</topic><topic>Insulin, Long-Acting</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Quality of life</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Swinnen, Sanne G</creatorcontrib><creatorcontrib>Dain, Marie-Paule</creatorcontrib><creatorcontrib>Aronson, Ronnie</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><creatorcontrib>Gerstein, Hertzel C</creatorcontrib><creatorcontrib>Pfeiffer, Andreas F</creatorcontrib><creatorcontrib>Snoek, Frank J</creatorcontrib><creatorcontrib>DeVries, J. Hans</creatorcontrib><creatorcontrib>Hoekstra, Joost B</creatorcontrib><creatorcontrib>Holleman, Frits</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Swinnen, Sanne G</au><au>Dain, Marie-Paule</au><au>Aronson, Ronnie</au><au>Davies, Melanie</au><au>Gerstein, Hertzel C</au><au>Pfeiffer, Andreas F</au><au>Snoek, Frank J</au><au>DeVries, J. Hans</au><au>Hoekstra, Joost B</au><au>Holleman, Frits</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>33</volume><issue>6</issue><spage>1176</spage><epage>1178</epage><pages>1176-1178</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C <7% without symptomatic hypoglycemia [less-than or equal to]3.1 mmol/l. RESEARCH DESIGN AND METHODS: In this 24-week trial, 973 insulin-naive type 2 diabetic patients on stable oral glucose-lowering drugs with A1C 7.0-10.5% were randomized to glargine once daily or detemir twice daily. Insulin doses were systematically titrated. RESULTS: 27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were -1.46 ± 1.09% for glargine and -1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017). Hypoglycemia risk was similar. Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001). Glargine doses were lower than detemir doses: 43.5 ± 29.0 vs. 76.5 ± 50.5 units/day (P < 0.001). CONCLUSIONS: In insulin-naive type 2 diabetic patients, glargine reached similar control as detemir, with more weight gain, but required significantly lower doses.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>20200301</pmid><doi>10.2337/dc09-2294</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2010-06, Vol.33 (6), p.1176-1178 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2875419 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Administration, Oral Biological and medical sciences Clinical trials Comparative analysis Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes. Impaired glucose tolerance Dosage and administration Drug Administration Schedule Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology Insulin - administration & dosage Insulin - analogs & derivatives Insulin - pharmacology Insulin - therapeutic use Insulin Detemir Insulin Glargine Insulin, Long-Acting Medical sciences Metabolic diseases Miscellaneous Original Research Patient outcomes Public health. Hygiene Public health. Hygiene-occupational medicine Quality of life Studies Treatment Outcome Type 2 diabetes Weight Gain - drug effects |
| title | 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A49%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=24-Week,%20Randomized,%20Treat-to-Target%20Trial%20Comparing%20Initiation%20of%20Insulin%20Glargine%20Once-Daily%20With%20Insulin%20Detemir%20Twice-Daily%20in%20Patients%20With%20Type%202%20Diabetes%20Inadequately%20Controlled%20on%20Oral%20Glucose-Lowering%20Drugs&rft.jtitle=Diabetes%20care&rft.au=Swinnen,%20Sanne%20G&rft.date=2010-06-01&rft.volume=33&rft.issue=6&rft.spage=1176&rft.epage=1178&rft.pages=1176-1178&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc09-2294&rft_dat=%3Cgale_pubme%3EA228905609%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=606623309&rft_id=info:pmid/20200301&rft_galeid=A228905609&rfr_iscdi=true |